Matches in Wikidata for { <http://www.wikidata.org/entity/Q92977579> ?p ?o ?g. }
- Q92977579 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q92977579 description "im Januar 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92977579 description "scientific article published on 26 January 2020" @default.
- Q92977579 description "wetenschappelijk artikel" @default.
- Q92977579 description "наукова стаття, опублікована 26 січня 2020" @default.
- Q92977579 name "Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)" @default.
- Q92977579 name "Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)" @default.
- Q92977579 type Item @default.
- Q92977579 label "Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)" @default.
- Q92977579 label "Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)" @default.
- Q92977579 prefLabel "Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)" @default.
- Q92977579 prefLabel "Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)" @default.
- Q92977579 P1433 Q92977579-1B373B9F-8BB1-4D4F-BC35-EC13731C4ABF @default.
- Q92977579 P1476 Q92977579-F0F72FD3-6BF0-425B-B58C-0CEF62FD0AF0 @default.
- Q92977579 P2093 Q92977579-05786000-998D-4CC6-B858-B5274E61C1A0 @default.
- Q92977579 P2093 Q92977579-0F16B8D8-3D54-4177-8EBC-C02935E216E4 @default.
- Q92977579 P2093 Q92977579-15C1F1FB-DEF9-4959-8D89-7507F65368EF @default.
- Q92977579 P2093 Q92977579-3C968759-4DA3-4BE7-9523-6C6C717B4EBB @default.
- Q92977579 P2093 Q92977579-80B08DD8-F985-4247-A839-AA2E5B6E4568 @default.
- Q92977579 P2093 Q92977579-9607716C-067D-4A29-B83E-169E82563423 @default.
- Q92977579 P2093 Q92977579-98AE706B-9F9B-4C36-B36D-1B00A7D0FBFB @default.
- Q92977579 P2093 Q92977579-9BA271EC-D7DB-48C8-B0CB-2341CB428668 @default.
- Q92977579 P2093 Q92977579-A1C2AECA-72CD-4549-BB71-65DA32BC674B @default.
- Q92977579 P2093 Q92977579-D00441BD-0C27-4FF0-96F9-D9D18E19D754 @default.
- Q92977579 P2093 Q92977579-DD39B256-2BA9-4534-A686-E121A1E275E3 @default.
- Q92977579 P2093 Q92977579-E3E5D95D-1D10-4F9F-B861-ED7E1609F9DC @default.
- Q92977579 P275 Q92977579-223d64e9-46f5-4756-b68f-1db51a00bba4 @default.
- Q92977579 P2860 Q92977579-0D3945C1-CB43-4B52-81D3-92840FFCE6EF @default.
- Q92977579 P2860 Q92977579-0DFCB42E-0200-4ABB-8392-61F419178568 @default.
- Q92977579 P2860 Q92977579-194E6F88-F459-43F8-A7BF-74057FB374D0 @default.
- Q92977579 P2860 Q92977579-30197E7F-B9F4-4090-B67A-9A1C09BC2A62 @default.
- Q92977579 P2860 Q92977579-30BD52E8-4EB9-4B55-B98D-D916B80E52F3 @default.
- Q92977579 P2860 Q92977579-31CC7CAF-BF40-4637-BF19-D2A69A774E61 @default.
- Q92977579 P2860 Q92977579-39165501-8E60-46CE-8CFD-8BCC3627C012 @default.
- Q92977579 P2860 Q92977579-3A756878-E4E3-4F53-B01C-0C285B51A342 @default.
- Q92977579 P2860 Q92977579-4A19F659-5C52-441D-8872-78D61546B9E9 @default.
- Q92977579 P2860 Q92977579-4C0BFCE7-9255-465A-9197-07F02B13522D @default.
- Q92977579 P2860 Q92977579-4DBD0441-C0F4-482A-AF00-8889C44225F4 @default.
- Q92977579 P2860 Q92977579-578316A9-D65A-471F-8954-710175DD461F @default.
- Q92977579 P2860 Q92977579-68B92CEC-ACE8-4F68-9962-1E9041F0967C @default.
- Q92977579 P2860 Q92977579-8FE8EE96-5C44-455F-9B62-0E619C3A9434 @default.
- Q92977579 P2860 Q92977579-A7FEAC24-B1AD-4F8C-8F2D-7CDD4C74B51F @default.
- Q92977579 P2860 Q92977579-AC41F865-B098-41A7-A6F5-86C75353AEB3 @default.
- Q92977579 P2860 Q92977579-C951EEE6-60A0-4BC1-A26E-AA55B7C2ECE5 @default.
- Q92977579 P2860 Q92977579-D0610E41-ECC9-48FD-8DF7-7957325EA125 @default.
- Q92977579 P2860 Q92977579-D7B07F1E-686F-42DC-A413-067BEB836A41 @default.
- Q92977579 P2860 Q92977579-DDD5B62E-4759-4054-97D9-906D1A44AD48 @default.
- Q92977579 P2860 Q92977579-DDE9D10E-4D11-427C-A627-F3BB4F9296D3 @default.
- Q92977579 P2860 Q92977579-E1F0222A-5C10-4730-B678-41651CCEE31B @default.
- Q92977579 P2860 Q92977579-E404C43B-2F9F-40C9-A4E2-EAAFBDBD5E24 @default.
- Q92977579 P2860 Q92977579-FA7CA51C-2C43-4D8B-A5B4-7B9EE43C3067 @default.
- Q92977579 P304 Q92977579-F17C127A-4700-4DE6-AA2E-1214C2AEC9DB @default.
- Q92977579 P31 Q92977579-5A272AC0-E993-4437-824B-5C65DA0C4135 @default.
- Q92977579 P356 Q92977579-4664EF8F-7679-4524-9458-9357356F0171 @default.
- Q92977579 P433 Q92977579-75519BBB-A420-4251-8F7C-47902E15D63C @default.
- Q92977579 P478 Q92977579-6D9A8EF6-6458-4E69-8BB2-0865B8BD9886 @default.
- Q92977579 P50 Q92977579-13052430-F9C9-40EE-85CC-33F820874B03 @default.
- Q92977579 P577 Q92977579-110D3E0D-666D-4621-ABDA-CF98D75BD331 @default.
- Q92977579 P6216 Q92977579-fc9fec0b-2f44-4f32-a428-d2c12089d82b @default.
- Q92977579 P698 Q92977579-AB5B98DE-6B7C-459F-A508-97A94F05E29B @default.
- Q92977579 P921 Q92977579-7DEF544C-1594-4C74-A643-8E028F60CB39 @default.
- Q92977579 P921 Q92977579-B5C0478C-FC8B-4DA2-BDA9-CB65E43EA7A3 @default.
- Q92977579 P921 Q92977579-C0A6E1DE-6AC8-4332-9E5A-E27C513A0987 @default.
- Q92977579 P932 Q92977579-6FBE6F00-9F39-49C2-A3B7-DCC5B0AC05A7 @default.
- Q92977579 P356 BMJOPEN-2019-033667 @default.
- Q92977579 P698 31988233 @default.
- Q92977579 P1433 Q17003470 @default.
- Q92977579 P1476 "Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)" @default.
- Q92977579 P2093 "Anthony M Joshua" @default.
- Q92977579 P2093 "H Woo" @default.
- Q92977579 P2093 "James Kench" @default.
- Q92977579 P2093 "Kate L Mahon" @default.
- Q92977579 P2093 "Lisa G Horvath" @default.
- Q92977579 P2093 "Lisa M Butler" @default.
- Q92977579 P2093 "Lucille Sebastian" @default.
- Q92977579 P2093 "Margaret M Centenera" @default.
- Q92977579 P2093 "Martin Stockler" @default.
- Q92977579 P2093 "Nariman Ahmadi" @default.
- Q92977579 P2093 "Phillip Stricker" @default.
- Q92977579 P2093 "Ruban Thanigasalam" @default.
- Q92977579 P275 Q34179348 @default.
- Q92977579 P2860 Q27853235 @default.
- Q92977579 P2860 Q29617472 @default.
- Q92977579 P2860 Q29617511 @default.
- Q92977579 P2860 Q29617512 @default.
- Q92977579 P2860 Q29620155 @default.
- Q92977579 P2860 Q30470623 @default.
- Q92977579 P2860 Q33389796 @default.
- Q92977579 P2860 Q33423263 @default.
- Q92977579 P2860 Q35888364 @default.
- Q92977579 P2860 Q36130090 @default.
- Q92977579 P2860 Q37463125 @default.
- Q92977579 P2860 Q37502364 @default.
- Q92977579 P2860 Q39018808 @default.
- Q92977579 P2860 Q39660526 @default.
- Q92977579 P2860 Q40248475 @default.
- Q92977579 P2860 Q41354811 @default.
- Q92977579 P2860 Q41844846 @default.
- Q92977579 P2860 Q44673099 @default.
- Q92977579 P2860 Q45044547 @default.